Breast Cancer | Specialty

The OncLive Breast Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of breast cancer, including those that are triple negative, hormone receptor positive, and/or HER2 positive. This page features news articles, interviews in written and video format, and podcasts that focus on treatment advances and ongoing research in breast cancer.

Lead Researcher Discusses Latest Pertuzumab Data in HER2+ Breast Cancer

August 12th 2017

Gunter von Minckwitz, MD, PhD, discusses the APHINITY results and their implication for the use of pertuzumab in patients with HER2-positive breast cancer.

Neoadjuvant T-DM1 Improves pCR in HER2+/HR+ Early Breast Cancer

August 11th 2017

Twelve weeks of neoadjuvant T-DM1 with or without endocrine therapy induced superior pathologic complete response compared with trastuzumab (Herceptin) plus endocrine therapy in patients with HER2-positive/HR-positive early breast cancer.

Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast Cancer

August 11th 2017

Mark D. Pegram, MD, director of the Breast Cancer Oncology Program at Stanford Medicine, discusses pertuzumab (Perjeta) plus trastuzumab (Herceptin) and chemotherapy for patients with HER2-positive breast cancer.

Treatment Considerations in Older Patients With Breast Cancer

August 10th 2017

Arti Hurria, MD, discusses the unique challenges with treating elderly patients with breast cancer and the exciting opportunities she envisions for advancing care in this setting.

Dr. Kuerer on Margins of DCIS

August 10th 2017

Henry M. Kuerer, MD, PhD, professor of surgery, The University of Texas MD Anderson Cancer Center, discusses margins of ductal carcinoma in situ (DCIS).

Pegram Discusses Latest Developments in HER2+ Breast Cancer

August 9th 2017

Mark Pegram, MD, discusses emerging treatments in HER2-positive breast cancer and his vision for the future of the field.

Sequenced Treatment Making Inroads in HER2-Positive Early Breast Cancer

August 2nd 2017

The introduction of targeted therapies has transformed HER2-positive breast cancer from an aggressive disease with poor outcomes to a highly manageable disease with potential for long-term survival.

Dr. Tolaney on Neoadjuvant HER2-Directed Therapy

August 2nd 2017

Sara M. Tolaney, MD, MPH, instructor of medicine, Harvard Medical School, attending physician of medical oncology, Dana-Farber Cancer Institute, discusses neoadjuvant HER2-directed therapy.

Identifying Actionable Biomarkers Crucial to Advancing Precision Medicine in MBC

July 28th 2017

While several biomarkers have been identified in patients with breast cancer, including ESR1 and PIK3CA mutations, not all of these are driver mutations that can be effectively targeted with treatment.

Trastuzumab Combos, Novel Agents Key to Advancing HER2+ Breast Cancer Care

July 28th 2017

Experts are trying to determine whether combination regimens with additional HER2-directed therapies or alternative therapies could improve responses in HER2-positive breast cancer without added toxicities.

European Commission Approves Frontline Fulvestrant for ER+ Breast Cancer

July 28th 2017

The European Commission has approved the use of fulvestrant (Faslodex) to treat estrogen receptor-positive, locally-advanced or metastatic breast cancer in postmenopausal women not previously treated with endocrine therapy.

Immune Checkpoint Agents Advance in Breast Cancer

July 27th 2017

Checkpoint inhibitors against PD-1 and PD-L1 have shown promise, both as monotherapies and in combination with chemotherapy for patients with triple-negative breast cancer.

Novel Therapeutic Strategies for Metastatic TNBC

July 21st 2017

Joyce O'Shaughnessy, MD, provides an update on existing research and a look at the future of novel therapeutic strategies for metastatic triple-negative breast cancer.

FDA Approves Neratinib for HER2+ Breast Cancer

July 18th 2017

The FDA has approved neratinib (Nerlynx) for the extended adjuvant treatment of patients with early stage, HER2-positive breast cancer following postoperative trastuzumab.

Dr. Hurria on Treatment Options for the Geriatric Population with Breast Cancer

July 17th 2017

Arti Hurria, MD, director, Cancer and Aging Research Program, co-leader, Cancer Control and Population Sciences Program, professor, Department of Medical Oncology and Therapeutics Research and Department of Population Sciences, discusses treatment for the geriatric patient population with breast cancer.

Dr. Rugo on Extended Adjuvant Hormone Therapy for Breast Cancer

July 17th 2017

Hope S. Rugo, MD, a professor of Medicine and director of the Breast Oncology Clinical Trials Program at the UCSF Helen Diller Family Comprehensive Cancer Center, discusses extended adjuvant hormone therapy for patients with breast cancer.

Dr. Pegram on Pertuzumab Plus Trastuzumab and Chemotherapy in Breast Cancer

July 15th 2017

Mark D. Pegram, MD, associate director, clinical research, director, Breast Cancer Program, Stanford Cancer Institute, discusses the current treatment landscape for patients with HER2-positive breast cancer.

Dr. Brufsky on the Disease-Free Survival of Aromatase Inhibitors for Breast Cancer

July 15th 2017

Adam M. Brufsky, MD, PhD, professor of Medicine, associate chief of Hematology/Oncology, co-director of the Comprehensive Breast Care Center, associate director of Clinical Investigation, University of Pittsburgh, discusses the 5 versus 10 year disease-free survival of aromatase inhibitors investigated in the NSAPB B-42 trial.

ODAC Votes to Recommend Approval for Trastuzumab Biosimilar MYL-1401O

July 14th 2017

The FDA’s Oncologic Drugs Advisory Committee voted 16-0 to recommend approval to MYL-1401O, the trastuzumab (Herceptin) biosimilar manufactured by Mylan Pharmaceuticals.

Dr. Burstein on the Results of the APT Trial for HER2+ Breast Cancer

July 13th 2017

Harold J. Burstein, MD, PhD, senior physician, associate professor of medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the results of the APT trial investigating adjuvant paclitaxel and trastuzumab (Herceptin) for node-negative HER2-positive breast cancer.